University of California at Los Angeles Health reported reducing red blood cell transfusions by almost 20% when it transitioned blood administration processes to all-electronic bar code scanning. The switch from the systems' previous hybrid electronic-paper format involved an eight-month bar coding project and an eight-month embedded clinical decision support project. The results of the change will be presented at a meeting of the Healthcare Information and Management Systems Society.
Georgetown University's Online MS in Finance Experience the Georgetown difference with our online MSF, transforming financial professionals into rising industry leaders. Engage in real-time interactive learning like no other. Nearly 90% of grads promoted or accepted new position with avg. salary increase of 43%. Begin a premier finance program today. Learn More.
A case study in The New England Journal of Medicine described a 23-year-old Florida woman who developed Zika virus symptoms such as widespread pruritic rash, fever and sore throat, as well as muscle and joint pain during the 23rd week of pregnancy, becoming the first case of locally acquired Zika virus in the US. The woman's pregnancy continued normally and her baby was born full-term, testing negative for Zika and without Zika-related birth defects.
Scientists from Baltimore's Johns Hopkins Bloomberg School of Public Health made modifications to the genetic makeup of Aedes aegypti mosquitoes that increased their resistance to the dengue virus. The findings were reported in the journal PLOS Neglected Tropical Diseases.
Takeda Pharmaceutical has entered into a collaboration with Maverick Therapeutics to develop the latter's T-cell redirection therapy platform for cancer treatments in a deal that could generate $125 million for Maverick. Takeda will pay an upfront option and equity fees, provide funding for research and development and also get the exclusive right to acquire Maverick for an undisclosed amount after five years.
The National Cancer Institute's new Cancer Therapy Evaluation Program will negotiate agreements between researchers and participating drugmakers to allow the use of specific agents in NCI-supported preclinical and clinical cancer studies. Six drugmakers have signed on to the initiative and agree to review proposals for listed agents within 60 days of receiving them from CTEP.
Paul M. Ness, MD, who has been editor-in-chief of the journal "Transfusion" since 2003, has elected to end his term of service in 2018. Thus, AABB is seeking candidates for the position. The editor-in-chief provides direction for the journal by setting policy, planning strategy, promoting contributions and determining overall content. Considered by many to be the foremost transfusion medicine research journal in the world, "Transfusion" contains original research articles, discussions with opposing viewpoints on controversial issues and key conference proceedings. In addition to blood banking and transfusion medicine topics, "Transfusion" covers issues concerning patient blood management, tissue transplantation and hematopoietic, cellular and gene therapies. The job description and position announcement can be found on the AABB website.